Characters: Mira (KPop Demon Hunters), Rumi (KPop Demon Hunters)
Additional Tags: Alternate Universe - Fantasy, Alternate Universe - Dungeons & Dragons, sorta - Freeform, Pre-Relationship, Tension, Unresolved Emotional Tension, Touch-Starved Mira (KPop Demon Hunters), Scars, Body Worship, again sorta, Elf Mira (Kpop Demon Hunters), Tiefling Rumi (Kpop Demon Hunters), Mira-centric (KPop Demon Hunters), no beta we die like jinu
Series: Part 3 of Discord Flash Fiction/Blurbs, Part 1 of FoggyMoss's Fantasy AU
Summary:
Everyone who has ever lain with Mira has felt entitled to her scars, asking for the stories while admiring them, caught in the thrall of bedding a warrior --except the tiefling woman she's traveled and shared a sleep roll with.
This much is clear. CBS is being “murdered,” as Scott Pelley calls what’s happening, not because of economics but because of politics. Economically, “60 Minutes” is a gold mine. Politically, Trump thinks it’s dangerous as hell because it tells the truth about him and his regime, and wants it killed. It’s important to see all this as a systematic effort by Trump to silence the truth about what he’s doing to America.
Trump’s increasingly corruption — rife with crony capitalism, corporate welfare, and payoffs to the powerful — is producing an increasingly corrupt economy in which everything depends on bribes and personal deals made by the biggest Republican loyalists and grifters, oligarchs and plutocrats, billionaires and multibillionaires, and monopolists.
When political and economic deal-making become personal transactions — when greed and payoffs replace trust — what happens? Authoritarianism replaces democracy. And an economy collapses, as it did at the end of America’s first Gilded Age, in the Great Crash of 1929, leading to the Great Depression.
One day we will look back on the murder of “60 Minutes” as one of the travesties of Trump’s despicable reign.
In the meantime, thank you Scott Pelley for telling the truth. Thank you, former “60 Minutes” producers, correspondents, and staff, for telling the truth.
And now, what do we do in the interest of the truth? We boycott CBS.
i think we should be ridiculing them more for this. you don't get to try and go all "queer website" when your staff likes to go on nuking sprees targeting the trans fem users
I'm an artist and medical student, and I use art to help me pay some bills.
I built a free, helpful tool because to help prevent other talented creatives from undercharging, as I really see this a lot online.
It's a calculator with a built in reality check
Input your survival costs and expenses
True billable hours
Get the rate you actually need to charge to hit a 20% (or whatever you choose) profit margin.
It generates the rate, a template negotiation email + final invoice.
Plan to keep this tool free, ad-free, and open to everyone.
🔗 Check your math: fairpaycalc.artres.xyz
If the "Thriving Rate" calculation empowers you to double your quote on your next job, please consider hitting the "Buy me a coffee"button. It keeps the server running and the code flowing <3
I am an artist and medical student and creator of Art-Res, a blog where I write and curate art resources. Hopefully you find art that bring
I love that four different people on my feed scheduled this joyous person to reblog by 8am on June 1. I look forward to seeing this a dozen more times today.
For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again
For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.
That routine just changed.
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.
This is not a minor update to an existing drug.
It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.
Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.
That means reducing from 365 injections a year down to just 52.
For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.
It represents relief.
How the Drug Actually Works
Understanding why this injection lasts a full week requires a quick look inside the body.
Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.
Awiqli works differently.
Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.
This attachment creates a slow-release reservoir.
Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...
The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.
Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...
What Comes Next
Awiqli is not standing alone in this space for long.
Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.
If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.
The broader direction of travel in diabetes care is unmistakable.
Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...
A Small Shot With Large Implications
It is easy to look at a once-weekly injection and see only a scheduling change.
But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.
Diabetes management has always asked a lot of people.
It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.
Anything that reduces that load, without reducing the quality of care, is worth taking seriously.
For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.
That is the real significance of what the FDA approved on March 26, 2026.
Not just a new drug.
A new way of keeping people healthy, one week at a time.
Literally the definition of imperialism and classism. Doesn’t matter how many peasants you sacrifice as long as the most powerful piece is left standing
